identification circulate tumor ctc free$$dna cfdna potential blood base biomarker capable prognostic predictive incorporate routine$$resistance limitation hamper ctc cfdna analysis understand precisely interpret emergent biomarker disease tumor type recognition challenge researcher clinician blood base biomarker development canadian trial cctg spring meeting toronto canada april workshop ctc cfdna interpretation datum ctc versus cfdna challenge regard disease evolution heterogeneity logistical consideration incorporation ctc cfdna trial ultimately routine objective workshop discussion current barrier implementation progress collaboration partnership researcher clinician anticipate consideration highlight workshop advance translational ultimately impact patient strategy patient outcome
